VIVUS Announces Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting

VIVUS, Inc. VVUS today announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction,will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C. Avanafil met all primary endpoints by demonstrating improvements from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP 2 and SEP 3) and improvement in the erectile function domain of International Index of Erectile Function. The study also indicated a favorable safety profile and successful intercourse was observed as early as 15 minutes after dosing, without any restrictions on food or alcohol.